A Large Open-Label Study of Venlafaxine in Depressed Outpatients by Community-Based Physicians
J Clin Psychiatry 1998;59(10):515-520
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: Studies to date suggest that venlafaxine is effective, well
tolerated, and safe in a broad spectrum of patients. We examined the clinical utility and
tolerability of venlafaxine in patients treated by community-based psychiatrists and
family physicians in a naturalistic clinical setting.
Method: Nineteen physicians each recruited 10 to 20 physicians to enroll
5 patients each maximum, diagnosed with DSM-IV major depression or dysthymia. The patients
were at least moderately ill (Clinical Global Impressions) with a score of at least 32 on
the Zung Self-Rating Depression Scale. After baseline clinical and laboratory assessments,
each patient received 37.5 mg of venlafaxine b.i.d., with adjustments possible at the 5
visits during the next 8 weeks.
Results: Of the 880 patients at baseline, 682 completed the 8-week study.
The daily doses of venlafaxine ranged between 18.75 mg and 375 mg, with 80% receiving
between 75 and 150 mg/day by 8 weeks. The intent-to-treat analysis revealed that at 8
weeks, 62% (522 of 843) of patients were either much or very much improved. Nausea was the
most frequent side effect, followed by somnolence, headache, and dry mouth.
Conclusion: Venlafaxine has good clinical utility and tolerability in a
community-based sample of a broad spectrum of depressed outpatients.